Failure Of Corneal Transplant, Glaucoma Patient Compliance, Preventing LASIK Infections The June issue of Ophthalmology, the journal of the American Academy of Ophthalmology, includes new insights on why some corneal transplants fail, why some patients skip their glaucoma medications, and why preventing infections after LASIK is a growing concern.
Source: www.medicalnewstoday.comIBM And Golden State Medical Supply Create Drug Safety Model To Help Combat Counterfeiting IBM (NYSE: IBM) and contract manufacturer and third party logistics provider Golden State Medical Supply (GSMS) announced the two companies have worked together to help drug companies comply with stringent
prescription drug pedigree regulations in advance of state and federal mandates. Global counterfeit drug sales will grow at almost twice the rate of legitimate pharmaceutical commerce by 2010 according to estimates from the Center for Medicine in the Public Interest.
Source: www.medicalnewstoday.comAssociation Between Rheumatoid Arthritis And Poor Sleep In Women According to a research abstract that will be presented on Wednesday, June 10, at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies, symptoms of Rheumatoid Arthritis (RA) negatively affect women's sleep. Sleep is further impaired by pain, depression and poor adherence to RA medications.
Source: www.medicalnewstoday.comHuman Genome Sciences Announces Completion Of Enrollment In Phase 2b Monthly-Dosing Trial Of Albuferon(R) Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that Novartis has completed enrollment and initial dosing in a Phase 2b clinical trial to evaluate the safety and efficacy of Albuferon(R) (albinterferon alfa-2b) administered monthly in combination with ribavirin in treatment-naive patients with genotypes 2 and 3 chronic hepatitis C. Albuferon is being developed by HGS and Novartis under an exclusive worldwide co-development and commercialization agreement entered into in June 2006.
Source: www.medicalnewstoday.comInnocoll Announces Provisional Findings From Its Three Phase 2 Clinical Trials Investigating CollaRx(R) GENTAMICIN TOPICAL Innocoll, Inc., a privately-held biopharmaceutical company, announced positive provisional findings from its three phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN TOPICAL for the treatment and prevention of infection in diabetic foot ulcers. Chronic ulcerations such as diabetic foot ulcers are often colonized or contaminated with bacterial pathogens that can prevent ulcers from healing.
Source: www.medicalnewstoday.com
# posted by Network @ 8:53 AM
